Biotech · Public company · Lexington, MA, US

Voyager Therapeutics, Inc.

Ticker VYGR · SEC CIK 0001640266

Track this companyFree. Adds Voyager Therapeutics, Inc. to your Dealase workspace and tells you when its record changes.

Clinical trials62 recruiting or active

Pipeline programs5From trials and the company's site

Disclosed deals0None found yet

Cash runwayNot availableNo recent cash burn filed

Pipeline5

VY7523Phase 2 · Alzheimer's Disease (AD)ClinicalTrials.gov · fetched Nov 12, 2026
Anti-AAV9 Total Antibody (TAb) AssayPhase 1 · Alzheimer s DiseaseClinicalTrials.gov · fetched Nov 12, 2026
VY1706 High DosePhase 1 · Alzheimer s DiseaseClinicalTrials.gov · fetched Nov 12, 2026
VY1706 Low dosePhase 1 · Alzheimer s DiseaseClinicalTrials.gov · fetched Nov 12, 2026
VY1706 Mid dosePhase 1 · Alzheimer s DiseaseClinicalTrials.gov · fetched Nov 12, 2026

An Open Label Dose Escalation Study of VY1706 in Participants With Early Alzheimer's DiseasePHASE1 · RECRUITING · started Sep 3, 2026ClinicalTrials.gov NCT07764146 · fetched Nov 12, 2026
VY7523-102: Randomized, Placebo-Controlled, Double-Blind, Multiple Ascending Dose Study in Participants With Early Alzheimer's DiseasePHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started Mar 3, 2025ClinicalTrials.gov NCT06874621 · fetched Nov 12, 2026
VY-AADC02 for Parkinson's Disease With Motor Fluctuations (RESTORE-1)PHASE1 · COMPLETED · started Oct 17, 2018ClinicalTrials.gov NCT03562494 · fetched Nov 12, 2026
Observational, Long-term Extension Study for Participants of Prior VY-AADC01 StudiesCOMPLETED · started Aug 24, 2018ClinicalTrials.gov NCT03733496 · fetched Nov 12, 2026
Safety and Efficacy Study of VY-AADC01 for Advanced Parkinson's DiseasePHASE1 · COMPLETED · started May 11, 2017ClinicalTrials.gov NCT03065192 · fetched Nov 12, 2026
Safety Study of AADC Gene Therapy (VY-AADC01) for Parkinson's DiseasePHASE1 · COMPLETED · started Oct 1, 2013ClinicalTrials.gov NCT01973543 · fetched Nov 12, 2026